|
1）Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res. 2004; 61: 663-70
|
|
|
|
2）Yamamuro M, Yoshimura M, Nakayama M, et al. Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extra-cellular sodium. Endocrinology. 2006; 147: 1314-21
|
|
|
|
|
|
3）Brilla CG, Pick R, Tan LB, et al. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res. 1990; 67: 1355-64
|
|
|
|
|
|
4）Guder G, Bauersachs J, Frantz S, et al. Com-plementary and incremental mortality risk predic-tion by cortisol and aldosterone in chronic heart failure. Circulation. 2007; 115: 1754-61
|
|
|
|
|
|
5）Staessen J, Lijnen P, Fagard R, et al. Rise in plasma concentration of aldosterone during ling-term angiotensin II suppression. J Endocrinol. 1981; 91: 457-65
|
|
|
|
|
|
6）Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999; 341: 709-17
|
|
|
|
|
|
7）Hamaguchi S, Kinugawa S, Tsuchihashi-Makaya M, et al. Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure. Am Heart J. 2010; 160: 1156-62
|
|
|
|
|
|
8）Delyani JA, Rocha R, Cook CS, et al. Eplerenone: a skelective aldosterone receptor antagonist (SARA). Cardiovasc Drug Rev. 2001; 19: 185-200
|
|
|
|
|
|
9）Pitt B, Remme WJ, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309-21
|
|
|
|
|
|
10）Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mile symptoms. N Engl J Med. 2011; 364: 11-21
|
|
|
|
|
|
11）Desai AS, Lewis EF, Li R, et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure an preserved ejection fraction. Am Heart J. 2011; 162: 966-72
|
|
|
|
|